New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Baptist GallwitzDept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It...

Full description

Bibliographic Details
Main Author:	Gallwitz B
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-05-01
Series:	Diabetes, Metabolic Syndrome and Obesity
Subjects:	type 2 diabetes diabetes therapy DPP-IV inhibitors incretin based therapy GLP-1 saxagliptin
Online Access:	https://www.dovepress.com/new-treatments-in-the-management-of-type-2-diabetes-a-critical-apprais-peer-reviewed-article-DMSO

Similar Items

Saxagliptin for type 2 diabetes
by: Chacra
Published: (2010-09-01)

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
by: Cobble Michael E, et al.
Published: (2012-01-01)

Incretin-based therapies for patients with type 1 diabetes: a meta-analysis
by: Lili Liu, et al.
Published: (2019-03-01)

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
by: Frederich Robert, et al.
Published: (2012-07-01)

The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial
by: Fiona J. Dore, et al.
Published: (2018-05-01)

Clinical Use of DPP-4 Inhibitors
by: Baptist Gallwitz
Published: (2019-06-01)

The new drug saxagliptin is now registrated in Russia
by: Editorial team Diabetes Mellitus
Published: (2010-12-01)

EFFECT OF DOUBLE HYPOGLYCEMIC THERAPY WITH METFORMIN AND SAXAGLIPTIN, ON ACHIEVEMENT OF GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES AND ADJUVANT OBESITY
by: Liliia Nikulina
Published: (2018-09-01)

Efficacy of Saxagliptin versus Mitiglinid in patients with type 2 diabetes and end-stage renal disease
by: Yukinao Sakai, et al.
Published: (2017-04-01)

Economic evaluation of the use of saxagliptin in the treatment of type 2 diabetes in Italy
by: Marco Cristiani, et al.
Published: (2010-06-01)

Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy
by: Anuj Kumar Borah, et al.
Published: (2022-05-01)

Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease
by: Federico Bernardini, et al.
Published: (2023-07-01)

Impact of baseline characteristics on glycemic effects of add‐on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus
by: Hui Fang, et al.
Published: (2020-07-01)

Linagliptin: a thorough characterization beyond its clinical efficacy
by: Maria Angela eSortino, et al.
Published: (2013-02-01)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
by: Farr AM, et al.
Published: (2016-08-01)

Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
by: Joanna Michałowska, et al.
Published: (2021-01-01)

Role of incretin based therapies in the treatment of diabetic kidney disease
by: Paola Fioretto, et al.
Published: (2018-11-01)

Vildagliptin and its role in the treatment of diabetes mellitus
by: Yury Shavkatovich Khalimov
Published: (2010-09-01)

Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up
by: Elena-Daniela Grigorescu, et al.
Published: (2023-08-01)

Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
by: Chiranjib Chakraborty, et al.
Published: (2017-01-01)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
by: Pia S. Pollack, et al.
Published: (2017-09-01)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
by: Schwartz S
Published: (2010-07-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

New prospects in the treatment of diabetes mellitus
by: Minara Shamkhalovna Shamkhalova, et al.
Published: (2012-12-01)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
by: Keizo Kanasaki, et al.
Published: (2019-05-01)

Chronic unpredicted mild stress-induced depression alter saxagliptin pharmacokinetics and CYP450 activity in GK rats
by: Zhengchao Xia, et al.
Published: (2016-01-01)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
by: Matthew P. Gilbert, et al.
Published: (2020-04-01)

Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment
by: Tao Tao, et al.
Published: (2018-02-01)

Control of type 2 diabetes mellitus: problems and prospects for their solution
by: Tatiana Ivanovna Romantsova, et al.
Published: (2009-12-01)

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
by: Kunika Saini, et al.
Published: (2023-05-01)

Enhanced Diabetic Wound Healing Using Electrospun Biocompatible PLGA-Based Saxagliptin Fibrous Membranes
by: Chen-Hung Lee, et al.
Published: (2022-10-01)

DPP4 in Diabetes
by: Diana eRöhrborn, et al.
Published: (2015-07-01)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
by: Baptist Gallwitz
Published: (2022-10-01)

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
by: Alina Babenko, et al.
Published: (2014-12-01)

Effect of Saxagliptin on Cisplatin-Induced Nephrotoxicity in Rats
by: Mary Eskander Attia, et al.
Published: (2022-01-01)

The Safety and Efficacy of Combining Saxagliptin and Pioglitazone Therapy in Streptozocin-Induced Diabetic Rats
by: Ahmed Mohamed Othman, et al.
Published: (2023-12-01)

Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies
by: Sanbao Chai, et al.
Published: (2023-07-01)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
by: Yury Ivanovich Suntsov
Published: (2012-03-01)

Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use
by: Chia-Jen Tsai, et al.
Published: (2022-11-01)